Sensor Integrated Biosensors (SIBs)

我们建议开发传感器集成生物反应器（SIB）作为一种工具，使研究人员和生产商的tissueconstruts监测其发展非破坏性的长期文化（长达28天）。该提案的创新之处在于将先进的传感、成像和监测技术纳入现有的最先进的生物反应器系统：准体内。增加的功能将允许对组织结构进行非侵入性原位监测，这将避免牺牲实验以在每个时间点收集数据的需要。SIB将由该联盟中建立的最终用户组开发，通过提供比目前可用的更严格控制的体外模型来加快再生医学产品的开发周期并提高生产的经济性。该项目将提供提供更快的组织生长的细胞培养系统，通过在流通系统中非破坏性地监测组织发育的能力，更准确地控制表型并提高效率。该支架将在使用RegenTec的“可注射骨”支架的骨再生的特定应用中进行验证。然而，该项目开发的结合传感器集成生物反应器（SIB）技术的准体内生物反应器将具有比骨再生更广泛的应用范围。生物反应器的初始尺寸对于研究应用来说是理想的，但是已经证明了多达36个准体内生物反应器可以并行操作，这使得它们具有内在的可扩展性，用于临床使用的干细胞繁殖。

We propose to develop sensor integrated bioreactors (SIBs) as a tool enabling researchers and producers of tissueconstucts to monitor their development non-destructively during long-term culture (up to 28 days). The innovation in thisproposal is the incorporation of advanced sensing, imaging and monitoring technologies into an existing state-of-the-artbioreactor system: Quasi-Vivo. The added functionality will allow for non-invasive, in situ monitoring of tissue constructswhich will avoid the need to sacrifice experiments to collect data at each time point. The SIBs will be exploited by the endusergroup established in this consortium, both to speed the development cycle of regenerative medicine products andimprove the economics of production by providing a more closely controlled in-vitro model than is currently available.This project will deliver cell culture systems that provide faster growth of tissue, more accurate control of phenotype andimproved efficiency through the ability to monitor tissue development non-destructively in a flow-through system. Thesystem will be validated in a particular application for bone regeneration using RegenTec's ' injectable bone' scaffold.However the Quasi-Vivo bioreactors incorporating the Sensor Integrated Bioreactors (SIBs) technology developed in thisproject will have a wider range of application than just bone regeneration. The initial size of the bioreactor will be ideal forresearch applications but it has already been demonstrated that up to 36 Quasi-Vivo bioreactors can be operated in parallelmaking them inherently scaleable for stem cell propagation for clinical use.